Lin Niu
Patent Agent

Lin is a registered US Patent Agent. He trained as a pharmaceutical scientist and immunologist and has a comprehensive understanding of research and development for both small molecules and biologics, including drug delivery, formulation and antibody engineering. Prior to joining VHPM, Lin worked at Mayo Clinic for four years and managed a large patent portfolio, including new chemical entity, biologics, nanoparticles, immunotherapy, vaccine, diagnostics and medical technology. He enjoys helping to bring new chemical and biotech solutions to the market for the world’s unmet or emerging needs. Lin also enjoys spending time with his lovely wife and kids and loves dancing with a soccer ball or basketball.

Lin’s Next Challenge: pull off a double “around-the-world” freestyle soccer juggling move.

University of Minnesota College of Pharmacy
Ph.D., Pharmaceutics, 2015

University of Minnesota Law School
M.S., Patent Law, 2015

Huazhong University of Science & Technology Tongji Medical College
M.S., Immunology, 2009

Huazhong University of Science & Technology School of Pharmacy
B.S., Pharmaceutical Science, 2007

Registered to practice before the United States Patent and Trademark Office.

Intradermal Delivery of Vaccine Nanoparticles using Hollow Microneedle Array Generates Enhanced and Balanced Immune Response. Journal of Controlled Release, 2019 Jan 28;294:268-278.

Polymeric Nanoparticles Encapsulating Novel TLR7/8 Agonists as Immunostimulatory Adjuvants for Enhanced Cancer Immunotherapy. Biomaterials, 2018 May;164:38-53.

Freeze Concentration-Induced PLGA and Polystyrene Nanoparticle Aggregation: Imaging and Rational Design of Lyoprotection. Journal of Controlled Release, 2017 Feb 28;248:125-132.

CD133-Targeted Paclitaxel Delivery Inhibits Local Tumor Recurrence in a Mouse Model of Breast Cancer. Journal of Controlled Release, 2013 Nov 10;171(3):280-7.

Targeting Transmembrane TNF-α Suppresses Breast Cancer Growth. Cancer Research. 2013 Jul 1;73(13):4061-74. Human Transmembrane TNF-alpha Monoclonal Antibody and Clinical Application. 2013, CN104140466A.

Effective Elimination of Cancer Stem Cells by Magnetic Hyperthermia. Molecular Pharmaceutics. 2013 Apr 1;10(4):1432-41.

Identification and Characterization of a Novel scFv Recognizing Human and Mouse CD133. Drug Deliv. and Transl. Res. 2012 September.

Influence of Reverse Signaling via Membrane TNF-alpha on Cytotoxicity of NK92 Cells. European Journal of Cell Biology. 2009 Mar;88(3):181-91.

Contact us today to learn how we can help you.